Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study
机构：[1]Respiratory Department, Chest Hospital Affiliated to Shanghai Jiao Tong University,Shanghai, China[2]Oncology Department, The Affiliated Hospital of Qingdao University,Qingdao, China[3]Department of Respiratory Medicine, Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China河南省肿瘤医院[4]Department ofThoracic Medical Oncology, Cancer Hospital Affiliated to the University of ChineseAcademy of Sciences, Hangzhou, China[5]Department of Thoracic Medical Oncology,Cancer Hospital Affiliated to the University of Chinese Academy of Sciences, Hangzhou,China浙江省肿瘤医院[6]Medical Oncology Department, AnHui Chest Hospital, Hefei, China[7]Department of Respiratory Medicine, The Fourth Hospital of Hebei Medical University,Shijiazhuang, China临床科室呼吸内科河北医科大学第四医院
第一作者机构：[1]Respiratory Department, Chest Hospital Affiliated to Shanghai Jiao Tong University,Shanghai, China
推荐引用方式(GB/T 7714)：
B. Han,T. Chu,Z.Yu,et al.Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study[J].ANNALS OF ONCOLOGY.2022,33(7):S1423-S1424.doi:10.1016/j.annonc.2022.08.059.
APA：
B. Han,T. Chu,Z.Yu,J. Wang,Y. Zhao...&N. Geng.(2022).Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study.ANNALS OF ONCOLOGY,33,(7)
MLA：
B. Han,et al."Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study".ANNALS OF ONCOLOGY 33..7(2022):S1423-S1424
医学